

# Intracoronary Doppler Flow Velocity Profiles





Figure 1

CVT-3146 30 µg

iv bonus

# Dose-Dependent Increase in Peak Flow Velocity Caused by CVT-3146




**CVT-3146 and Coronary Flow Velocity  
Duration of Effect:**


<b>Dose (n)</b>	<b>Duration <math>\geq 2.5</math> Baseline</b>	
	<b>Mean <math>\pm</math> SEM</b>	
10 $\mu$ g (4)	0	
30 $\mu$ g (4)	0	
100 $\mu$ g (3)	$0.2 \pm 0.2$ minutes	
300 $\mu$ g (4)	$2.2 \pm 1.3$ minutes	
400 $\mu$ g (8)	$2.8 \pm 0.8$ minutes	
500 $\mu$ g (4)	$2.9 \pm 1.3$ minutes	

**Figure 3**

## Time Course of APV Ratio (CVT-3146 400 $\mu$ g)



## Time Course of Heart Rate (CVT-3146 400 $\mu$ g)



Time Course of Blood Pressure  
(CVT-3146 400  $\mu$ g)




Figure 6

All Drug-Related Adverse Events Were Mild and  
Transient

<b>Adverse Event</b>	<b>All Doses</b>		<b>400 µg</b>	
	<b>(n = 36)</b>		<b>(n = 9)</b>	
chest discomfort	3		3	
increased heart rate	3		1	
hypotension	2		2	
flushing	2		1	
shortness of breath	2		0	
funny taste in mouth	1		0	
sensation in mouth, sinus, and chest	1		0	
headache	1		0	
tingling in hands	1		1	
heart racing	1		1	
bradycardia	1		1	
lightheadedness	1		1	
cough	1		0	
nausea and vomiting	1		0	

**Figure 7**

Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14





Figure 15






Figure 16




Figure 17




Figure 18